← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue was $0, while Net income increased 29.0% to ($149.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $0Watch
- Profitability — Net income ($149.3M)Watch
- Cash generation — Free cash flow ($128.7M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 4 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
PLIANT THERAPEUTICS, INC.: If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.
Where the revenue comes from
Fiscal 2023, as PLIANT THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
Leadership changes
From PLIANT THERAPEUTICS, INC.'s own filings, the day they're filed.
- David E. · director · departureeff. 2026-04-14
- I. Pyott · director · departureeff. 2026-04-14
- Minnie Kuo · Chief Operating Officer · appointmenteff. 2025-12-10
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about PLIANT THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.